# Rgenta Therapeutics

Source: https://onco.cc/companies/rgenta-therapeutics/  
OnCo record `rgenta-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rgenta Therapeutics makes tablet medicines that act on a gene's RNA message rather than its protein; its lead drug switches off MYB, the driver of adenoid cystic carcinoma, a rare cancer of the salivary glands.

## Summary

Rgenta Therapeutics, Inc., of Woburn, Massachusetts, develops oral small-molecule RNA-targeting medicines: small molecule glues that stabilise the interaction between a target RNA and the splicing machinery so that the target RNA is degraded. Its lead programme RGT-61159 inhibits production of the oncogenic transcription factor MYB and is in a phase 1a/b trial in relapsed or refractory adenoid cystic carcinoma and colorectal cancer (NCT06462183); it received FDA orphan drug designation for adenoid cystic carcinoma in September 2025, and in October 2026 the company announced an end-of-phase 2 meeting with the FDA and alignment on a phase 3 design. Preclinical work extends RGT-61159 to acute myeloid leukaemia, and the company has a CNS programme and an RSwitch gene-regulation technology. In January 2024 it joined the Leukemia & Lymphoma Society Therapy Acceleration Program, which provided strategic funding. Its first registered cancer trial, NCT06462183, was posted on ClinicalTrials.gov in June 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Rgenta Therapeutics Inc
- HQ: Woburn, MA
- Type: biotech
- Website: https://www.rgentatx.com/

## Notes

- Company website, news list and the January 2024 LLS release read on 29 October 2026. The domain rgenta.com is an unrelated parked domain; the company's site is rgentatx.com. Founding year not stated on the pages read. Venture rounds were not read and are not recorded.

## Sources

- Official website: https://www.rgentatx.com/
- News and press releases: https://www.rgentatx.com/news
- ClinicalTrials.gov: phase 1a/b trial of RGT-61159 (NCT06462183): https://clinicaltrials.gov/study/NCT06462183

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Adenoid cystic carcinoma](https://onco.cc/cancers/adenoid-cystic-carcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/)
- targets: [MYB](https://onco.cc/targets/myb/)
- companies: [Leukemia & Lymphoma Society Therapy Acceleration Program](https://onco.cc/companies/lls-therapy-acceleration-program/)

---
JSON: https://onco.cc/api/v1/entities/rgenta-therapeutics.json